Muscle wasting in cancer

N Johns, N A Stephens, K C H Fearon

Research output: Contribution to journalLiterature reviewpeer-review


Skeletal muscle loss appears to be the most significant clinical event in cancer cachexia and is associated with a poor outcome. With regard to such muscle loss, despite extensive study in a range of models, there is ongoing debate as to whether a reduction in protein synthesis, an increase in degradation or a combination of both is the more relevant. Each model differs in terms of key mediators and the pathways activated in skeletal muscle. Certain models do suggest that decreased synthesis accompanied by enhanced protein degradation via the ubiquitin proteasome pathway (UPP) is important. Murine models tend to involve rapid development of cachexia and may represent more acute muscle atrophy rather than the chronic wasting observed in humans. There is a paucity of human data both at a basic descriptive level and at a molecular/mechanism level. Progress in treating the human form of cancer cachexia can only move forwards through carefully designed large randomised controlled clinical trials of specific therapies with validated biomarkers of relevance to underlying mechanisms. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Original languageEnglish
Pages (from-to)2215-29
Number of pages15
JournalInternational Journal of Biochemistry and Cell Biology
Issue number10
Publication statusPublished - Oct 2013


Dive into the research topics of 'Muscle wasting in cancer'. Together they form a unique fingerprint.

Cite this